Annual Cash & Cash Equivalents
$132.19 M
-$18.84 M-12.47%
30 September 2024
Summary:
Anavex Life Sciences annual cash & cash equivalents is currently $132.19 million, with the most recent change of -$18.84 million (-12.47%) on 30 September 2024. During the last 3 years, it has fallen by -$19.92 million (-13.10%). AVXL annual cash & cash equivalents is now -13.10% below its all-time high of $152.11 million, reached on 30 September 2021.AVXL Cash And Cash Equivalents Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly Cash And Cash Equivalents
$132.19 M
-$6.57 M-4.73%
30 September 2024
Summary:
Anavex Life Sciences quarterly cash and cash equivalents is currently $132.19 million, with the most recent change of -$6.57 million (-4.73%) on 30 September 2024. Over the past year, it has dropped by -$18.84 million (-12.47%). AVXL quarterly cash and cash equivalents is now -16.10% below its all-time high of $157.56 million, reached on 30 June 2021.AVXL Quarterly Cash And Cash Equivalents Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
AVXL Cash And Cash Equivalents Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly |
|---|---|---|
| 1 y1 year | -12.5% | -12.5% |
| 3 y3 years | -13.1% | -13.1% |
| 5 y5 years | +495.8% | +495.8% |
AVXL Cash And Cash Equivalents High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | |
|---|---|---|---|---|---|
| 3 y | 3 years | -13.1% | at low | -14.6% | at low |
| 5 y | 5 years | -13.1% | +495.8% | -16.1% | +495.8% |
| alltime | all time | -13.1% | -16.1% |
Anavex Life Sciences Cash And Cash Equivalents History
| Date | Annual | Quarterly |
|---|---|---|
| Sept 2024 | $132.19 M(-12.5%) | $132.19 M(-4.7%) |
| June 2024 | - | $138.76 M(-0.5%) |
| Mar 2024 | - | $139.39 M(-3.0%) |
| Dec 2023 | - | $143.76 M(-4.8%) |
| Sept 2023 | $151.02 M(+1.3%) | $151.02 M(-2.5%) |
| June 2023 | - | $154.82 M(+0.9%) |
| Mar 2023 | - | $153.47 M(+6.9%) |
| Dec 2022 | - | $143.62 M(-3.7%) |
| Sept 2022 | $149.16 M(-1.9%) | $149.16 M(-2.6%) |
| June 2022 | - | $153.20 M(-0.1%) |
| Mar 2022 | - | $153.34 M(+1.5%) |
| Dec 2021 | - | $151.15 M(-0.6%) |
| Sept 2021 | $152.11 M(+420.0%) | $152.11 M(-3.5%) |
| June 2021 | - | $157.56 M(+107.7%) |
| Mar 2021 | - | $75.86 M(+60.2%) |
| Dec 2020 | - | $47.36 M(+61.9%) |
| Sept 2020 | $29.25 M(+31.8%) | $29.25 M(+5.9%) |
| June 2020 | - | $27.62 M(+4.0%) |
| Mar 2020 | - | $26.56 M(-3.3%) |
| Dec 2019 | - | $27.46 M(+23.8%) |
| Sept 2019 | $22.19 M(-3.2%) | $22.19 M(+4.4%) |
| June 2019 | - | $21.25 M(+9.2%) |
| Mar 2019 | - | $19.46 M(-6.1%) |
| Dec 2018 | - | $20.72 M(-9.7%) |
| Sept 2018 | $22.93 M(-16.4%) | $22.93 M(-11.2%) |
| June 2018 | - | $25.83 M(+0.7%) |
| Mar 2018 | - | $25.66 M(-8.5%) |
| Dec 2017 | - | $28.05 M(+2.2%) |
| Sept 2017 | $27.44 M(+198.7%) | $27.44 M(+10.7%) |
| June 2017 | - | $24.79 M(+6.2%) |
| Mar 2017 | - | $23.35 M(+10.3%) |
| Dec 2016 | - | $21.16 M(+130.3%) |
| Sept 2016 | $9.19 M(-39.9%) | $9.19 M(-5.6%) |
| June 2016 | - | $9.73 M(-18.6%) |
| Mar 2016 | - | $11.95 M(-13.7%) |
| Dec 2015 | - | $13.85 M(-9.4%) |
| Sept 2015 | $15.29 M | $15.29 M(+92.1%) |
| June 2015 | - | $7.96 M(+26.2%) |
| Mar 2015 | - | $6.31 M(-9.6%) |
| Date | Annual | Quarterly |
|---|---|---|
| Dec 2014 | - | $6.98 M(-3.9%) |
| Sept 2014 | $7.26 M(+2004.3%) | $7.26 M(-11.2%) |
| June 2014 | - | $8.18 M(-11.0%) |
| Mar 2014 | - | $9.19 M(+9486.7%) |
| Dec 2013 | - | $95.90 K(-72.2%) |
| Sept 2013 | $345.10 K(+2927.2%) | $345.10 K(>+9900.0%) |
| June 2013 | - | $1600.00(+220.0%) |
| Mar 2013 | - | $500.00(-99.4%) |
| Dec 2012 | - | $79.80 K(+600.0%) |
| Sept 2012 | $11.40 K(-91.5%) | $11.40 K(-37.4%) |
| June 2012 | - | $18.20 K(-89.8%) |
| Mar 2012 | - | $178.60 K(+1862.6%) |
| Dec 2011 | - | $9100.00(-93.2%) |
| Sept 2011 | $134.70 K(-49.1%) | $134.70 K(-89.0%) |
| June 2011 | - | $1.22 M(>+9900.0%) |
| Mar 2011 | - | $3600.00(-99.2%) |
| Dec 2010 | - | $423.80 K(+60.1%) |
| Sept 2010 | $264.70 K(-24.6%) | $264.70 K(-81.8%) |
| June 2010 | - | $1.46 M(+909.3%) |
| Mar 2010 | - | $144.50 K(+588.1%) |
| Dec 2009 | - | $21.00 K(-94.0%) |
| Sept 2009 | $351.00 K(+5384.4%) | $351.00 K(-52.7%) |
| June 2009 | - | $742.60 K(+843.6%) |
| Mar 2009 | - | $78.70 K(>+9900.0%) |
| Dec 2008 | - | $600.00(-90.6%) |
| Sept 2008 | $6400.00(>+9900.0%) | $6400.00(+10.3%) |
| June 2008 | - | $5800.00(-37.0%) |
| Mar 2008 | - | $9200.00(-81.1%) |
| Dec 2007 | - | $48.60 K(>+9900.0%) |
| Sept 2007 | $0.00(-100.0%) | $0.00(-100.0%) |
| June 2007 | - | $100.00(-99.3%) |
| Mar 2007 | - | $15.00 K(+233.3%) |
| Dec 2006 | - | $4500.00(-63.4%) |
| Sept 2006 | $12.30 K(+1130.0%) | $12.30 K(-38.2%) |
| June 2006 | - | $19.90 K(>+9900.0%) |
| Mar 2006 | - | $100.00(0.0%) |
| Dec 2005 | - | $100.00(-90.0%) |
| Sept 2005 | $1000.00(-96.4%) | $1000.00 |
| Sept 2004 | $28.10 K | - |
FAQ
- What is Anavex Life Sciences annual cash & cash equivalents?
- What is the all time high annual cash & cash equivalents for Anavex Life Sciences?
- What is Anavex Life Sciences annual cash & cash equivalents year-on-year change?
- What is Anavex Life Sciences quarterly cash and cash equivalents?
- What is the all time high quarterly cash and cash equivalents for Anavex Life Sciences?
- What is Anavex Life Sciences quarterly cash and cash equivalents year-on-year change?
What is Anavex Life Sciences annual cash & cash equivalents?
The current annual cash & cash equivalents of AVXL is $132.19 M
What is the all time high annual cash & cash equivalents for Anavex Life Sciences?
Anavex Life Sciences all-time high annual cash & cash equivalents is $152.11 M
What is Anavex Life Sciences annual cash & cash equivalents year-on-year change?
Over the past year, AVXL annual cash & cash equivalents has changed by -$18.84 M (-12.47%)
What is Anavex Life Sciences quarterly cash and cash equivalents?
The current quarterly cash and cash equivalents of AVXL is $132.19 M
What is the all time high quarterly cash and cash equivalents for Anavex Life Sciences?
Anavex Life Sciences all-time high quarterly cash and cash equivalents is $157.56 M
What is Anavex Life Sciences quarterly cash and cash equivalents year-on-year change?
Over the past year, AVXL quarterly cash and cash equivalents has changed by -$18.84 M (-12.47%)